key: cord-0769725-84eqxed1
authors: Stephenson, Anne L.
title: Financial impacts of the COVID-19 pandemic on cystic fibrosis care: Lessons for the future (Commentary) A.L. Stephenson()
date: 2021-12-18
journal: J Cyst Fibros
DOI: 10.1016/j.jcf.2021.08.029
sha: 7301c2e682d7f4aa35497ba0e5aa557f707bab97
doc_id: 769725
cord_uid: 84eqxed1

nan

The COVID-19 pandemic has had a devastating effect on the global economy but the financial impact on health care delivery may not be as obvious as in some other sectors. Further, these impacts may vary by country depending on the severity of the lock downs and pre-existing healthcare structures. In the current issue, Sawicki et al. highlight a very important, yet often overlooked issue of the financial impact of the pandemic on those living with a chronic health condition.

As outlined by Sawicki et al. [1] , the CF model of care is guideline-driven and involves regular, quarterly in-person visits where CF patients are assessed by a multidisciplinary team to optimize health. In addition, individuals with CF may require in-patient hospitalization when needed to treat acute exacerbations or manage complications of CF. In the study by Sawicki et al. 286 CF clinic Program Directors in the United States (US) were surveyed and 63% felt the pandemic led to detrimental financial changes within their institutions due to the pandemic ranging from redeployment and layoffs to reduced salaries. Further, lower reimbursement rates for medical services provided resulted in either fewer patients being seen or less time spent with patients while some disciplines carried out non-reimbursable activities. This was particularly true for nurses, respiratory therapists, pharmacists, and social workers -all of whom are key members of the multi-disciplinary team providing care to the CF population. Lastly, the issue of licensure when providing virtual care for patients living outside of local health regions was found to be yet another financial barrier to care.

The financial impact of the pandemic has affected countries differently although there are similarities as well. Clinical staff redeployment and hiring freezes were seen in many countries that grappled with rising COVID cases. Even in countries with relatively low infection rates such as Australia and New Zealand, there has been a direct financial impact on the CF care model with far fewer in-person clinical visits and a reduction in CF-associated hospitalizations. The pandemic has also reduced the availability of CFtrained healthcare professionals since CF pulmonologists, respiratory therapists, and physiotherapists have been involved in providing direct COVID care and thus are less available for CF care. A reduction in CF staff comes at a time when many patients actually need more support from their CF team members. Our experience has been that during the pandemic, CF patients need a higher R This paper is part of a Supplement supported by the Cystic Fibrosis Foundation. level of social worker support due to increased stress and anxiety brought on by the adverse financial impacts of COVID.

With respect to healthcare delivery, the pandemic has resulted in a dramatic and abrupt pivot from in-person to virtual care yet providing the expected level of multidisciplinary care under this virtual model has its challenges. Virtual care often lacks typical objective measures (i.e. lung function, sputum cultures) used to evaluate one's health. Expedited by the pandemic, the availability of home spirometry has dramatically increased in many countries adding further financial burden to patients, CF programs, and CF patient organizations, all of whom are looking for ways to ensure people living with CF are adequately monitored. In addition, modifications to reimbursement for care were necessary in those countries where physicians work on a fee-for-service basis and payment schemes for virtual visits conducted via telephone or videoconferencing were lacking. In Canada, as in many countries, a process for reimbursement for virtual care was quickly implemented although it is unclear whether or not this process will continue raising further concerns about the viability of virtual care in the post-pandemic era. Furthermore, video-assisted calls add a layer of complexity due to the increased administrative support and time needed to create and disseminate virtual teleconference links to the appropriate patients and healthcare providers. In addition, this requires that patients and providers have a reliable, affordable, high-speed internet connection which can be a limiting factor for many.

Conducting a greater number of visits virtually has resulted in several distinct advantages for patients. With no travel involved, virtual appointments have greatly reduced both the expense and the time away from school or work that is normally required. In addition, the risk of infection related to both COVID and CF pathogens is eliminated. However, there could be both direct and indirect additional costs to patients in the era of virtual care such as the cost of home spirometry monitoring equipment. In the absence of such equipment, however, a decline in lung function that goes undetected due to lack of home spirometry could ultimately result in the need for intravenous antibiotics and loss of income from being off work. Finally, we may see an increase in chronic Pseudomonas infection due to lack of sputum screening and timely eradication therapy. The downstream effects of the pandemic may in fact increase the direct and indirect costs to patients.

Interestingly, during the pandemic the number of patients hospitalized for CF-related pulmonary exacerbations has dramatically declined in many countries. The cause of this decrease is likely multi-factorial. As mentioned by Sawicki et al., the initiation of highly effective modulators in the US occurred just prior to the pandemic and certainly played a role in reducing the need for hospitalizations. However, in Canada, a significant reduction in the need for hospitalization was noted during 2020 despite having very limited access to highly effective modulators. The reduction in hospitalization was likely fuelled by the pandemic due to patients' fear of entering a hospital setting and possibly being exposed to COVID. However, this reduction could also be explained by individuals with CF having more time during lockdowns to focus on therapy, reduced exposure to common viruses due to isolation and increased overall infection control measures. Whatever the reasons, it is possible that hospital administration may question the need for a large CF inpatient team given the reduced volume of in-patient care. As such, this may result in reduced financial support to CF programs from hospital administration ultimately impacting healthcare delivery. CF programs might consider a proactive rather than reactive approach to the future of CF care and consider focusing resources and staffing on outpatient based care given the shifting tides.

With respect to the many charitable organizations and foundations around the world, the pandemic has dealt a crushing financial blow. Widespread job losses have resulted in far fewer donations and nearly all key in-person fundraising events such as walks and galas, have had to be cancelled. As a result, funding support to CF clinical, research and training programs has been drastically reduced or halted completely having a direct impact on the care delivered to the CF community. For instance, Cystic Fibrosis Canada has provided Clinic Incentive Grants to the 42 accredited CF programs across the country. These funds are used to support clinical care, continuing education of healthcare team members and data entry for the Canadian CF Registry. In 2020, Cystic Fibrosis Canada was forced to withhold this financial support entirely and in 2021, the funding was reduced to 25% of its pre-pandemic level. This is a significant financial shock to CF care clinics in Canada as these funds are used to support salaries for crucial multidisciplinary staff and support continuing medical education which in turn, allows clinics to provide the high level of care that individuals living with CF have come to expect.

Finally, conducting clinical research has also been extremely challenging during the pandemic. Securing research funding is even more competitive as many national funding bodies have focused their attention to supporting COVID-19 specific research which leaves less money for other areas of study. Industrysponsored clinical trials are more agile due to increased resources; however, shutting down research activities due to the pandemic may have led to sites not being available or able to participate in trials in a timely way, which becomes particularly important when trials have competitive enrollment. Research funds can be important sources of revenue to support CF research staff and at times, support salaries for multi-disciplinary team members who are involved in clinical trials. This is yet another financial hit to the CF programs that may be under-appreciated.

Overall, the pandemic has most definitely had a detrimental financial impact on delivery of healthcare to individuals living with CF. According to Sawicki et al., the majority of respondents felt that the financial support for CF programs would recover back to prepandemic levels although this remains to be seen. Given the positive response to virtual care by the CF community, the pandemic may be responsible for a shift in the paradigm of CF care. CF clinicians and healthcare providers must be creative about how to financially sustain this new model of care so that we can ensure the highest level of quality care that the CF community expects moving forward.

There are no direct conflicts of interest relevant to this commentary. Unrelated to this work, ALS receives a stipend from Cystic Fibrosis Canada for her role as Medical Director of the Canadian Cystic Fibrosis Registry; ALS has received funds from Vertex Pharmaceuticals for consultant work related to the CF Annual educational program.

Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future